In 2017, the UK Government published the Life Science Industrial Strategy, billed as “A report to the Government from the life sciences sector” which contained “recommendations for our world leading life sciences industry to drive growth, increase productivity, improve the use of data, reinforce our science base, deepen our skills and secure benefits for patients throughout the United Kingdom”.
This was closely followed by the Life Sciences Sector Deal, a set of agreements that was seen as phase one of implementing the Strategy’s recommendations.
“The deal brings together the government with universities, charities and more than 25 businesses – large and small – to make a joint commitment to invest in all parts of the United Kingdom.” Life Sciences Sector Deal (2017)
Then, in 2018, the Life Sciences Sector Deal 2 was published, described as further agreements that “deepens our partnership with industry, universities and charities”.
In these documents, developing clusters of industry activity throughout the country (especially in support of existing life science activity) was seen as a high priority. One of the areas highlighted in the reports is the “Northern Powerhouse”.
The Northern Powerhouse includes the North West, North East, and Yorkshire regions – they account for 15 million people and one million private sector businesses. If this area were a country, it would be amongst the biggest economies in Europe.
In the Northern Powerhouse area, there are over 1,000 life science and healthcare companies. Employees in the life science sector here now account for 21% of the UK’s total life science workforce, having grown by over 9% since 2012.
In 2015, the area exported £7.3bn in pharmaceutical products – 45% of all medicinal exports.
By 2017, the value of the sector to the Northern Powerhouse region was estimated to be over £13.6bn – with more investment already secured (including £1.6bn over 5 years from the Northern Health Science Alliance in response to the first Life Sciences Sector Deal).
While the government talks more broadly about the Northern Powerhouse, we also think it’s useful to think about clusters and activities at a regional level, so the rest of this post will only consider the life science sector in the North West…
Local Clusters In The North West Hub
Even while we talk about the North West as a hub, it’s important to understand that there are several smaller localised clusters throughout the region, each with its own speciality. These include:
Cheshire is also home to Alderley Park, “the UK’s largest single site life science campus”. The 400 acre site hosts 4 national institutions, 2000 innovators, and has attracted £247m investment. Most recently it was chosen as a site for a Lighthouse Laboratories (a network of laboratories involved in the diagnostic testing for COVID-19) and a Validation Centre of Excellence. It even has its own podcast series.
Speke was the site of the first commercial production of a biologic with Eli Lilly’s manufacture of insulin. And the area has gone on to become one of Europe’s leading bio-manufacturing clusters employing over 1,830 people in companies such as Allergan, AstraZeneca, Elanco, and Seqirus (check out our company profiles section below for more detailed information). The big name companies manufacturing here are supported by a growing biotechnology community, healthcare companies, and a “strong analytical and clinical supply presence”.
Invest Liverpool highlights 3 key criteria that make the area such an appealing prospect for the life science industries:
Deep regulatory expertise – manufacturing teams across the region have worked with regulators such as the MHRA for many years
Dynamic pool of workers – with such a concentration of companies, there is a “dynamic talent pool of experienced staff” at all levels
Strong local supply-chain – small and medium sized companies serving the sector in a variety of ways from medical packaging to specialist logistics
LIverpool is also home to Knowledge Quarter Liverpool (KQ Liverpool), described as “the largest cluster of science, health, education and cultural minds in the region” from institutions and organisations including the University of Liverpool, Liverpool School of Tropical Medicine, Liverpool John Moores University, Liverpool Science Park, Sensor City, Accelerator, the new £429m Royal Hospital and the £157m Clatterbridge Cancer Centre.
Over the next 5-years, a further £2bn investment is predicted for KQ Liverpool.
The city is also home to Manchester Science Park – a campus with over 150 science and tech companies, and Citylabs Campus – the “largest clinical academic campus in Europe” that brings together the NHS, academic, the scientific community, and industry.
The Life Science Activities Of The North West
Taking all these local clusters into consideration, the North West forms quite a distinctive life science hub.
There is currently an encouraging diversity to the life science industry activities across the North West.
The area has taken a strong and well established reputation for manufacturing and continued to build on that, especially within the high-value area of biopharmaceuticals. In addition, there has been a move towards earlier stages of the drug development process – the North West is now home to over 30% of the UK’s contract research organisations (CROs).
Why the Life Science Industries Pick the North West
Local Gov’s 2020 analysis showed that the North West was second only to Cambridge for life science job vacancy numbers (and ahead of Oxford). It went on to suggest that the low cost of living compared to the South and East, were an advantage for the area in attracting both companies and talent.
But a successful industrial hub is more than just a collection of businesses – it is usually also home to a supportive local environment, academic institutions, and infrastructure that encourages start-ups and growth.
Supportive local environment
“Through the largest investment in research and development in 40 years and ambitious plans to build on our world-leading performance, we are creating more opportunities and are committed to supporting science and innovation in the North. The North is already home to many of our brightest minds and centres of scientific excellence, and plays an important role in developing the innovations that will drive productivity and the region’s future economic growth.” UK Government
The UK Government commitment to the North will undoubtedly have increased company confidence in investing here. Support included provision for improving things such as transport infrastructure. The specifics of implementing the plan are to be decided alongside local stakeholders but specific projects have included the creation of two publicly-funded research centres at Alderley Park (one focused on combating drug-resistant “superbugs”, and one focused on medicines technology).
The Northern Health Science Alliance (NHSA) is the North’s health partnership organisation of NHS hospitals, universities, and academic health science networks that works with industry nationally and internationally to plan and encourage investment in the area. It was named as delivery partner in the North for the Government’s Life Sciences Industrial Strategy Sector Deal.
There are a range of other organisations across the region, including Bionow – a not-for-profit membership organisation that supports life science sector businesses across the North. They run a series of events and conferences, act as an advocate for the North, and work with members to develop the sector’s presence in this area.
And, of course, there are also smaller, more localised, initiatives including the likes of the HealthTec Cluster within Sci-Tech Daresbury in Liverpool. This joint project from the Innovation Agency and the Science and Technology Facilities Council promotes collaboration by bringing together over 40 public organisations, private companies, and academic institutions from across the region. The aim is to increase the presence of the health technology industry in the North West and in its first year it saw 15% growth in sector activity.
The HealthTec Cluster spans four local enterprise partnerships in the North West. They come together to share knowledge and facilities specifically designed to develop health technology businesses and to transform healthcare – #HealthTecNW
“Many of our companies are collaborating with universities…We’ve got around 140,000 life science graduates coming out of 8 universities within an hour’s drive of Alderley park, so we’re an absolutely prime position to match our new graduates with many of the different companies that we have on site… our relationships with universities are absolutely fundamental” Dr Kath Mackay, managing director at Bruntwood SciTech’s Alderley Park
Universities across the whole of the Northern Powerhouse region, provide a quarter of the UK’s STEM graduates.
The North West specifically is home to 3 universities that rank in the top 200 universities worldwide – University of Manchester, University of Lancaster, and University of Liverpool. These are research-intensive universities that strongly support both spin-outs and the development of a highly skilled local talent pool.
This makes the North West an attractive option for employers looking for a strong and skilled workforce as well as access to top-class academic research partners.
Infrastructure to support start-ups and growth
Local Gov’s 2020 analysis of research funding allocation found that the North West had secured £18.5bn in grant funding from the 5 main scientific funding councils since 2010 – more than either Oxford or Cambridge.
There is a strong infrastructure across the North West region to support start-ups and growth.
As mentioned above, Manchester is home to Manchester Science Park – a campus with over 150 science and tech companies. The site was “purposefully designed to maximise customer interaction in order for innovative ideas to develop, and valuable partnerships to form”.
The Citylabs Campus in Manchester offers clients “unique direct access to the hospital Trust’s clinical resources, researchers, clinicians and procurement teams, as well as a specialist growth support and events programme”.
And Alderley Park in Cheshire offers an Accelerator programme of “start-up and scale-up support to early stage and growing life science businesses on their journey to success”. There’s also a £5m incubation fund to support companies establishing themselves in the park.
Other Innovation Hubs (similar to the Alderley Park Accelerator) exist in Sci-Tech Daresbury and Manchester University’s Incubator. These sites offer a gathering of expertise, a place for collaboration, and access to resources and professional services.
Sci-Tech Daresbury is trying to make a difference for the businesses that call us home. We are aiming to deliver an additional 10,000 high-value jobs at Sci-Tech Daresbury over the next 20 years.
They have 3 facilities across the North West: an R&D site in Alderley Park, a pharmaceutical manufacturing site in Macclesfield, and vaccine R&D and manufacturing operations in Speke, Merseyside. Across the three sites, the company currently employs approximately 4,700 people.
In Alderley Park, the company has retained some R&D capabilities despite moving most of those operations to a new site in Cambridge. It was the sale of their premises here, to Manchester Science Parks in 2014, that eventually led to the creation of Alderley Park life science campus.
In Macclesfield, the manufacturing site has been operational since 1966, initially owned by ICI. AstraZeneca has invested approximately £120m to upgrade the manufacturing facility in recent years. The site now employs 1800 people in manufacturing alone. It is AstraZeneca’s second largest manufacturing site, and the European centre for packing.
In June 2020, the company was given approval for a new facility at the Macclesfield site, which will employ a further 72 people.
In Speke, the company’s biologics team (operating as MedImmune) work on the UK’s child flu vaccination programme, developing new vaccines annually in response to new strains and mutations, delivering 20 million flu vaccines a year. Over recent years, the company has invested around £75m to centralise vaccine activities here and increase production capabilities.
After announcing expansion plans for the Speke facility in 2013, Terts Ashibi – who headed up programme management at MedImmune – was quoted as saying “We’re growing very quickly but we’re struggling to get that skills base… That’s the challenge for us as a company and the solution starts in the classroom“.
Nutricia (part of Danone) operates a medical nutrition manufacturing site in Liverpool that employs 320 people. There has been a medical nutrition facility on this site for over 100 years and products manufactured here are distributed to over 50 countries around the world.
In 2010, the company invested £20 million in the site’s development and manufacturing capabilities for its protein-free medical nutrition brands. More recently, £5 million was invested in 2017/18 to further upgrade the manufacturing facility.
Due to the nature of the products produced here (for those with cow’s milk allergies or metabolic disorders), the plant operates an “entirely protein free factory environment” – the only site in the UK and Ireland to do so.
Teva is one of the world’s largest pharmaceutical companies, specialising in “generic and specialist” medicines.
The company’s Runcorn, Cheshire site employs 500 people and manufactures “difficult to make medicines” – in the form of sterile liquid products – for the treatment of respiratory conditions. The site manufactures more than 480 million doses of sterile medicine every year.
In addition, there are 2 R&D centres, developing sterile drug products and sterile device technology. The site is also home to the company’s Sterile Training Academy, a “centre of excellence within Teva for sterile manufacturing, safety and compliance training”.
Check out the brilliant video below for a look inside Teva’s Runcorn facility, and see the stages involved in taking ingredients all the way through to packaged final products.
Recipharm is a leading Contract Development and Manufacturing Organisation.
The company lists their activities as including “manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development”. They work with a range of customers from small R&D, to large pharmaceutical companies.
The company’s Cheshire inhalation medical device site manufactures products including metered dose inhalers (MDI), dry powder inhalers (DPI) and nasal sprays, and is both MHRA and FDA approved. The site and all its 450 employees were transferred from Sanofi to Recipharm in 2018.
Seqirus is the world’s number 2 influenza vaccine supplier. It was created in 2015 when parent company CSL acquired Novartis’ influenza vaccine business.
The company’s Speke, Liverpool site is a “Centre of Excellence for egg-based influenza vaccines, one of the biggest biotech sites in Europe and the only injectable influenza vaccine manufacturer in the UK.”
It employs over 700 people and is responsible for production of around half of the UK’s seasonal flu vaccine, as well as exporting vaccines to countries around the world.
The company has invested over £60 million in the site in recent years, including £22 million in 2016…